Endocrine Abstracts

Estrogen Receptor alpha (ER) is the key driver in the majority of all breast cancers, and considered the main target for therapy. However, resistance to treatment is common and biomarkers to facilitate optimal treatment selection are urgently needed. Even though the vast majority of breast cancer patients are female, breast cancer can develop in men as well. Using chromatin immunoprecipitation followed by massive-parallel sequencing (ChIP-seq), we identified the genome-wide ch...

The androgen receptor (AR) plays a pivotal role in prostate cancer development, progression and hormone-therapy resistant disease. AR requires a permissive epigenetic state at distinct chromatin regions to facilitate gene expression programs. The vast majority of AR sites are found at active enhancer regions, hallmarked by histone modification H3K27Ac and devoid of repressive markers including H3K27me3. In search for novel biomarkers for prostate cancer prognostication, we per...

Estrogen receptor α (ERα) is a key transcriptional regulator in the majority of breast cancers. ERα-positive patients are frequently treated with tamoxifen, but resistance is common. Through ChIP-seq analyses, we presviously identified direct target genes of ERα acting in complex with SRC1, SRC2 or SRC3 (Zwart et al., 2011 EMBO J). Only the 111 genes there were under direct control of ERα in conjunction with SRC3 (but not the other two p160s) predicted...